使用警語:中文譯文來源為 AI 翻譯,僅供參考,實際內容請以英文原文為主
Operator
Operator
Greetings, and welcome to the Align Technology, Inc. third-quarter 2016 earnings conference call. At this time, all participants are in a listen-only mode. A question-and-answer session will follow the formal presentation. (Operator Instructions) As a reminder, this conference is being recorded.
各位好,歡迎參加 Align Technology, Inc.2016 年第三季財報電話會議。目前所有與會者皆為只聽模式。正式簡報結束後將進行問答環節。(接線員指示) 提醒各位,本次會議將被錄音。
I would now like to turn the conference over to your host, Ms. Shirley Stacy, VP Corporate and Investor Communications. Thank you, Ms. Stacy. You may begin.
現在我想把會議交給本次主持人,企業與投資人溝通副總裁 Shirley Stacy 女士。謝謝您,Stacy 女士。您可以開始了。
Shirley Stacy - VP of Corporate Communications and IR
Shirley Stacy - VP of Corporate Communications and IR
Good afternoon, and thank you for joining us. I'm Shirley Stacy, Vice President of Corporate Communications and Investor Relations. Joining me from today's conference call is Joe Hogan, President and CEO; David White, CFO; and John Morici, incoming CFO.
各位下午好,感謝各位加入我們。我是 Shirley Stacy,企業傳播與投資人關係副總裁。今天與我一同參與電話會議的有總裁暨執行長 Joe Hogan;財務長 David White;以及即將上任的財務長 John Morici。
We issued third-quarter 2016 financial results today via market wire, which is available on our website at investor.aligntech.com. Today's conference call is being audio webcast and will be archived on our website for approximately 12 months. A telephone replay will be available today by approximately 5:30 p.m. Eastern Time through 5:30 p.m. Eastern Time on November 21st.
我們今天已透過市場新聞稿發布 2016 年第三季財務結果,可於 investor.aligntech.com 的網站上查閱。今天的電話會議將以音訊網路直播,並將在我們網站上存檔約 12 個月。電話重播將於今日約美東時間下午 5:30 提供。並將持續至 11 月 21 日美東時間下午 5:30。
To access the telephone replay, domestic callers should dial 877-660-6853 with conference number 13646649 followed by #. International callers should dial 201-612-7415 with the same conference number. As a reminder, the information that the presenters discuss today will include forward-looking statements, including statements about Align's future events, product outlooks, and the expected financial results for the fourth quarter of 2016.
如欲收聽電話重播,美國境內來電者請撥 877-660-6853,輸入會議編號 13646649 後按 #。國際來電者請撥 201-612-7415,並輸入相同會議編號。提醒各位,今天簡報者所討論的資訊將包含前瞻性陳述,包括關於 Align 未來事件、產品展望,以及 2016 年第四季預期財務結果的陳述。
These forward-looking statements are only predictions, and involve risks and uncertainties that are set forth in more detail in our most recent periodic reports filed with the Securities and Exchange Commission. Actual results may vary significantly, and Align expressly assumes no obligation to update any forward-looking statements.
這些前瞻性陳述僅為預測,並涉及風險與不確定性;相關內容已在我們最近向美國證券交易委員會提交的定期報告中更詳細說明。實際結果可能有重大差異,Align 明確表示不承擔更新任何前瞻性陳述的義務。
We have posted historical financial statements, including the corresponding reconciliation and our third-quarter conference call slides on our website under Quarterly Results. Please refer to these files for more detailed information.
我們已在網站「季度結果」專區發布歷史財務報表(含相應調節表)以及第三季電話會議簡報投影片。如需更詳細資訊,請參閱這些檔案。
With that, I'll turn the call over to Align Technology's President and CEO, Joe Hogan. Joe?
接下來,我把電話交給 Align Technology 總裁暨執行長 Joe Hogan。Joe?
Joe Hogan - President, CEO and Director
Joe Hogan - President, CEO and Director
Thanks, Shirley. Good afternoon, everyone, and thank you for joining us. Today in conjunction with our Q3 earnings announcement, we also announced the retirement of David White, who will step down as CFO on November 10.
謝謝你,Shirley。各位下午好,感謝各位加入我們。今天配合第三季財報公告,我們也宣布財務長 David White 將退休,並將於 11 月 10 日卸任財務長職務。
David has been a key contributor to our business growth over the past three years, and the Board and I want to thank David for his dedication, and wish him the best in his retirement. We are fortunate that David will stay on with the Company through February 2017 to work on certain planning and ERP implementation projects, and ensure a smooth transition with his successor, John Morici.
過去三年,David 一直是推動我們業務成長的重要貢獻者;董事會與我都要感謝 David 的投入,並祝福他退休生活一切順利。我們很幸運 David 將留任公司至 2017 年 2 月,協助特定規劃與 ERP 導入專案,並確保與其繼任者 John Morici 的交接順利。
I'm pleased to have John join Align and here with us today on this call. I've known and respected John for years. I've watched him grow and kept up with his career for over 16 years, and have a huge amount of confidence in him. John is an experienced CFO and General Manager who can partner with me and the leadership team to accelerate progress.
我很高興 John 加入 Align,並在今天的電話會議與我們同在。我多年來一直認識並敬重 John。我看著他成長,並在超過 16 年的時間裡持續關注他的職涯發展,對他非常有信心。John 是一位經驗豐富的財務長與總經理,能與我及領導團隊合作,加速推進各項進展。
He has financial experience across several large dynamic companies, including Abbott Labs, GE, NBC Universal, so he can scale with the growth we expect from Align in the upcoming years. John doesn't officially start until the 10th, so we won't make him answer any questions about the business, but he will be happy to take a couple of your questions during Q&A about why he's so excited about joining Align.
他在多家大型且充滿活力的公司累積了財務經驗,包括 Abbott Labs、GE、NBC Universal,因此能配合我們預期 Align 未來幾年的成長規模化運作。John 要到 10 日才正式上任,所以我們不會讓他回答任何關於業務的問題;但在問答環節,他很樂意回答各位幾個問題,談談他為何對加入 Align 感到如此興奮。
Let me now turn to our third-quarter results. On our call today, I'll provide some financial highlights, and then briefly discuss the performance of our two operating segments, clear aligners and intra-oral scanners. Dave will provide more detail on our financial results and discuss our outlook for the fourth quarter. Following that, I'll come back and summarize a few key points and open up the call to questions.
接下來談談我們第三季的業績。在今天的電話會議中,我將提供一些財務重點,並簡要說明我們兩個營運部門——透明牙套與口內掃描器——的表現。Dave 將更詳細說明財務結果,並討論我們對第四季的展望。之後我會回來總結幾個重點,並開放提問。
Q3 was a solid quarter with revenue margin and EPS each above the high end of our guidance. Our results were driven by record Invisalign case volume, up 20.5% year-over-year, reflecting growth across all customer channels and geographies, as well as continued demand for iTero scanners. The Q3 North American Clear Aligner volume was up slightly, 0.9% sequentially, consistent with historical Q2 to Q3 norms, and up 14.5% year-over-year.
第三季表現穩健,營收、毛利率與每股盈餘(EPS)皆高於我們財測區間的上緣。我們的結果主要由創紀錄的 Invisalign 病例量帶動,年增 20.5%,反映各客戶通路與各地區的成長,以及 iTero 掃描器需求持續。第三季北美透明牙套病例量季增小幅上升 0.9%,符合歷史上第二季到第三季的常態,且年增 14.5%。
On a sequential basis, North American Ortho's were up, driven by teenage cases, which increased 20% from Q2, and contributing to another record quarter for Ortho utilization. This was offset by North America GP volumes, which were down sequentially, primarily due to a seasonally slower period for GPs as well as weaker dental market. The GP channel remains challenging, particularly among low-volume practices.
以季比來看,北美矯正科(Ortho)病例量上升,主要由青少年病例帶動,較第二季增加 20%,並促成矯正科使用率再創單季新高。此增長被北美一般牙科(GP)病例量的季減所抵銷,主要原因是 GP 進入季節性較淡的期間,以及牙科市場較疲弱。GP 通路仍具挑戰,尤其是低病例量的診所。
On a year-over-year basis, North American Ortho volume was strong and GP growth rate was solid, especially considering tougher 2015 comps. We believe North America still has a lot of headroom for growth, as we continue to execute our strategic initiatives, including new products and technology innovation, evolving our go-to-market approach and leveraging the TFM model that has been so successful in EMEA, and rolling out new teen initiatives, including a new consumer campaign next year.
以年比來看,北美矯正科病例量表現強勁,GP 成長率也相當穩健,特別是在 2015 年比較基期更具挑戰的情況下。我們認為北美仍有很大的成長空間;我們將持續推動策略性計畫,包括新產品與技術創新、調整我們的市場進入策略、借鏡並運用在 EMEA 已非常成功的 TFM 模式,以及推出新的青少年計畫,包括明年新的消費者行銷活動。
In the GP market specifically, we are working to scale two very successful practice development programs led by key opinion leaders, increasing our focus on DSOs and large group practices. And in October, we began piloting Invisalign Go, our new product engineered specifically for GP dentists, with full commercial launches second half of 2017.
就 GP 市場而言,我們正致力於擴大兩項由關鍵意見領袖主導、非常成功的診所發展計畫,同時加大對 DSOs 與大型團體診所的聚焦。此外,我們在 10 月開始試點 Invisalign Go,這是專為 GP 牙醫設計的新產品,預計於 2017 年下半年全面商業化上市。
Q3 Invisalign volume for international doctors was roughly flat, 0.5% sequential, driven by strong growth in Asia-Pacific, offset by summer seasonality in EMEA, especially in Southern Europe, where doctors and their patients typically take extended holidays. On a year-over-year basis, international Invisalign volume was up 33.8%, reflecting continued strong performance across both EMEA and APAC.
第三季國際醫師的 Invisalign 病例量大致持平,季增 0.5%;主要由亞太地區強勁成長帶動,但被 EMEA 的夏季季節性所抵銷,尤其在南歐,醫師及其病患通常會有較長的假期。以年比來看,國際 Invisalign 病例量年增 33.8%,反映 EMEA 與 APAC 皆持續強勁的表現。
In EMEA, Q3 volume was up 27% year-over-year, reflecting continued adoption of Invisalign in core markets like Spain and France, as well as rapid growth from expansion into new country markets, including Eastern Europe, Benelux, and Nordic regions. In Asia-Pacific, we had another record quarter, with volumes up sequentially and up 44.3% year-over-year, led by China and Japan.
在 EMEA,第三季病例量年增 27%,反映 Invisalign 在西班牙、法國等核心市場持續被採用,以及拓展至新國家市場所帶來的快速成長,包括東歐、比荷盧與北歐地區。在亞太地區,我們再度創下單季新高,病例量季增且年增 44.3%,主要由中國與日本帶動。
Most APAC country markets have recorded shipments -- had record shipments, including China, Japan, Taiwan, Hong Kong and Southeast Asia markets. In addition, we continue to see positive industry response at major events across the region, including the Guangdong Ortho Society meeting, one of the biggest in China.
多數 APAC 國家市場的出貨量——都創下紀錄出貨量,包括中國、日本、台灣、香港以及東南亞市場。此外,我們也持續在區域內各大活動中看到正面的產業回饋,包括廣東省正畸學會年會(Guangdong Ortho Society meeting),這是中國規模最大的活動之一。
During Q3, we announced multiple innovations that enhance Invisalign treatment planning and predictability of treatment outcome. Invisalign G7, which we announced in October, built on earlier Invisalign G Series releases with new features to fine-tune certain tooth movement and deliver excellent treatment outcomes that doctors expect, especially with teens.
在第三季期間,我們宣布多項創新,提升 Invisalign 治療規劃能力以及治療結果的可預測性。我們於 10 月宣布的 Invisalign G7,在先前 Invisalign G 系列版本的基礎上新增功能,可更精細地調整特定牙齒移動,並提供醫師所期待的優異治療成果,尤其是在青少年病例上。
We also announced ClinCheck Pro 5.0, which has new features that deliver an exceptional user experience and new visuals along with increased control for doctors during treatment planning.
我們也宣布推出 ClinCheck Pro 5.0,具備可帶來卓越使用者體驗的新功能與全新視覺效果,並在治療規劃期間為醫師提供更高的控制度。
Finally, we were very excited to announce our new one-week wear recommendation for all Invisalign teen in full products. Based on a predictability of the Invisalign system and our experience, as well as patient case data shared by our customers who have been prescribing weekly Aligner changes, we believe that, for most cases, one-week wear can deliver shorter treatment times for patients and greater efficiency for Invisalign practices.
最後,我們非常興奮地宣布,針對所有 Invisalign teen in full 產品推出新的「每副配戴一週」建議。基於 Invisalign 系統的可預測性與我們的經驗,以及客戶分享的患者病例數據(這些客戶一直採用每週更換一次矯正器),我們相信在多數病例中,每副配戴一週可為患者帶來更短的治療時間,並提升 Invisalign 診所的效率。
Turning to the teen market, 162,000 teenagers started treatment with Invisalign over the past 12 months, an increase of 21% compared to the same 12-month period in 2015. For Q3, the total number of teenagers using Invisalign increased 19% sequentially and up 17.4% year-over-year, driven by continued adoption worldwide.
談到青少年市場,過去 12 個月共有 162,000 名青少年開始使用 Invisalign 進行治療,較 2015 年同期的 12 個月期間成長 21%。第三季青少年使用 Invisalign 的總數量較前一季增加 19%,並較去年同期成長 17.4%,主要受全球持續採用所帶動。
In Q3, we saw a strong uptake among teenagers using Invisalign outside the United States, up 36% year-over-year, with strong growth, particularly from Asia-Pacific, which now accounts for 51% of the total international teen cases. For North American Ortho's, Q3 teen volume increased about 14%, was lower than expected, and not as robust as Q3 last year when we ran several teen-specific promotions that drove incremental teen volume.
第三季,我們看到美國以外地區青少年使用 Invisalign 的採用強勁成長,年增 36%,其中以亞太地區成長尤為顯著;目前亞太已占國際青少年病例總量的 51%。就北美矯正科醫師(Ortho)而言,第三季青少年量約成長 14%,低於預期,也不如去年第三季強勁;去年第三季我們推出多項青少年專屬促銷活動,帶動了額外的青少年量。
Q3 will serve as a good baseline as we head into next year, where we intend to launch a major teen program and a new direct-to-consumer campaign, with greater investment in targeting teenagers more directly than ever have before. While we are pleased with our Q3 results, our incoming case receipts in North America were lower than expected. We believe case receipts were impacted primarily due to a weaker dental market for GPs, as well as a lack of teen promotional activity for Europe orthos.
第三季將成為我們邁向明年的良好基準;明年我們計畫推出一項大型青少年計畫,以及新的直面消費者(DTC)行銷活動,並加大投資,以前所未有的方式更直接鎖定青少年。雖然我們對第三季結果感到滿意,但北美的新增病例收件量低於預期。我們認為病例收件量主要受到一般牙醫(GP)牙科市場較疲弱的影響,以及歐洲矯正科醫師缺乏青少年促銷活動所致。
Today, with more than a month into Q4, I'm pleased to report that our North America case receipts have since improved and that demand outlook appears solid. Dave will provide more details in his business outlook.
目前第四季已過一個多月,我很高興報告北美病例收件量已改善,需求展望看來穩健。Dave 將在他的業務展望中提供更多細節。
Our integrated consumer marketing campaigns in North America, EMEA, and APAC, leveraged traditional paid media, search, digital marketing, PR, and social media to engage consumers at every point in the consumer purchase journey. Consumer interest and demand for Invisalign treatment continues to grow.
我們在北美、EMEA 與 APAC 的整合式消費者行銷活動,運用傳統付費媒體、搜尋、數位行銷、公關與社群媒體,在消費者購買旅程的每個環節與消費者互動。消費者對 Invisalign 治療的興趣與需求持續成長。
In Q3, we celebrated a major patient milestone, and launched a global social media and advertising campaign to promote the London-based 4 millionth Invisalign patient. We promoted this milestone as a part of our partnership with Operation Smile, with Align Technology donating $1 to Operation Smile for every public share of a photo of a person's smile on Facebook, twitter, or Instagram, with the hashtag of #4millionsmiles for a total donation of up to $1 million.
第三季,我們慶祝一項重要的患者里程碑,並啟動全球社群媒體與廣告活動,宣傳位於倫敦的第 400 萬名 Invisalign 患者。我們將此里程碑作為與 Operation Smile 合作的一部分進行推廣;Align Technology 承諾,對於每一次在 Facebook、twitter 或 Instagram 上公開分享某人微笑照片並使用 #4millionsmiles 標籤的行為,將捐贈 1 美元給 Operation Smile,總捐款上限為 100 萬美元。
The 4 Million Smiles campaign has been a great success in driving a reach and awareness of the Invisalign brand around the globe, and with this hashtag being seen over 51 million times around the world.
「400 萬微笑」活動在提升全球 Invisalign 品牌觸及與知名度方面非常成功,該標籤在全球被觀看超過 5,100 萬次。
North America, we saw positive gains in our consumer engagement and conversion metrics, including web traffic conversion, soft locator searches and consumer opting for more information on treatment. In September, we partnered with the AAO at the start of the New York City Fashion Week to highlight the best fashion accessory ever, a great smile as a result of Invisalign treatment.
在北美,我們的消費者互動與轉換指標出現正向提升,包括網站流量轉換、soft locator 搜尋,以及消費者選擇取得更多治療資訊。9 月,我們在紐約時裝週開幕之際與 AAO 合作,強調最棒的時尚配件:透過 Invisalign 治療所帶來的迷人笑容。
The Invisalign brand was a primary event sponsor, and created an Invisalign lounge experience to showcase the power of a confident smile through Invisalign patient testimonials, iTero scans, and consults with New York City area orthodontists. In EMEA, our consumer outreach focused primarily on our 4 Million Smiles campaign and the launch of the Patient Experience Program in the UK market. This program is aimed at helping Invisalign providers create an excellent patient experience, and includes learning modules aimed at practice staff to help them discuss Invisalign treatment with prospective new patients.
Invisalign 品牌是主要活動贊助商,並打造 Invisalign 休憩區體驗,透過 Invisalign 患者見證、iTero 掃描,以及與紐約市地區矯正科醫師的諮詢,展示自信笑容的力量。在 EMEA,我們的消費者外展主要聚焦於「400 萬微笑」活動,以及在英國市場推出的 Patient Experience Program(患者體驗計畫)。該計畫旨在協助 Invisalign 提供者打造卓越的患者體驗,並包含面向診所員工的學習模組,協助他們與潛在新患者討論 Invisalign 治療。
In Asia-Pacific, our consumer marketing campaigns are focused on demand generation in key markets, including China, Australia, New Zealand, Hong Kong, Japan. In China, for example, our Big Bang Consumer Outreach Program has focused on consumer engagement through Invisalign providers and social media KOL's, or key opinion leaders. This campaign delivered a 380% year-over-year increase in consumer web traffic, is on track to deliver 150,000 lead generations behind this campaign. We will also continue to see traction in Australian teen campaign.
在亞太地區,我們的消費者行銷活動聚焦於在關鍵市場創造需求,包括中國、澳洲、紐西蘭、香港與日本。例如在中國,我們的 Big Bang 消費者外展計畫聚焦於透過 Invisalign 提供者與社群媒體 KOL(關鍵意見領袖)提升消費者互動。該活動帶動消費者網站流量年增 380%,並有望透過此活動帶來 150,000 筆潛在客戶名單(lead generation)。我們也將持續看到澳洲青少年活動的進展。
In Q3, our scanner business revenues were up 35% sequentially and up 274% year-over-year, reflecting a record number of units shipped in the quarter, primarily in North America. Demand for the iTero element scanner has stabilized. At the recent ADA meeting in Denver, we announced new software upgrades for our market-leading iTero Element intraoral scanner and Invisalign outcome simulator.
第三季,我們的掃描儀業務營收較前一季成長 35%,較去年同期成長 274%,反映本季出貨台數創新高,主要來自北美。iTero element 掃描儀的需求已趨於穩定。在丹佛近期舉行的 ADA 會議上,我們宣布為市場領先的 iTero Element 口內掃描儀與 Invisalign outcome simulator 推出新的軟體升級。
Only iTero scanners provide an optimized Invisalign scanning and treatment experience that includes the enhanced Invisalign outcome simulator 4.0 application, now with Invisalign 3-D progress tracking in patient simulation sharing. The 3-D progress tracking feature gives Invisalign providers the ability to compare patients' new scan with a specific stage of ClinCheck Pro treatment plan to visually assess and communicate Invisalign treatment progress with an easy-to-read, color-coded tooth movement report that allows the doctors to know how each tooth is tracking.
只有 iTero 掃描儀能提供最佳化的 Invisalign 掃描與治療體驗,其中包含強化版 Invisalign outcome simulator 4.0 應用程式,現已在患者模擬分享中加入 Invisalign 3-D 進度追蹤。3-D 進度追蹤功能讓 Invisalign 提供者能將患者的新掃描與 ClinCheck Pro 治療計畫的特定階段進行比較,以視覺化方式評估並溝通 Invisalign 治療進度;同時提供易讀的、以顏色編碼的牙齒移動報告,讓醫師了解每顆牙齒的追蹤情況。
Use of the iTero scanners for Invisalign case submissions in place of PVS impressions continues to expand. The Q3 total Invisalign cases submitted with a digital scanner worldwide increased 39.6%, which reflects a record 48.4% from North America and 22% from international doctors. While these scans are predominantly from our own iTero scanner, we are also seeing some uptake from 3M's True Def and Sirona's Omnicam scanners.
以 iTero 掃描儀提交 Invisalign 病例、取代 PVS 印模的使用持續擴大。第三季全球以數位掃描儀提交的 Invisalign 病例總數增加 39.6%,其中北美占比創紀錄達 48.4%,國際醫師占比為 22%。雖然這些掃描主要來自我們自有的 iTero 掃描儀,但我們也看到 3M 的 True Def 與 Sirona 的 Omnicam 掃描儀有一定程度的採用。
We also completed the final validation process for 3Shape's TRIOS scanner -- TRIOS Standard, TRIOS Color, and TRIOS 3, in which Invisalign providers with the TRIOS scanner can now submit digital scans as part of the Invisalign case submissions.
我們也完成了 3Shape 的 TRIOS 掃描儀(TRIOS Standard、TRIOS Color 與 TRIOS 3)的最終驗證流程;配備 TRIOS 掃描儀的 Invisalign 提供者現在可在提交 Invisalign 病例時一併提交數位掃描。
Now I'll turn to the supply agreement we announced in July with SmileDirectClub for the emerging Doctor-directed at-home aligner market. Our agreement with SmileDirectClub is to manufacture non-Invisalign aligners for simple cases, which include up to 20 sets of aligners with no IPR attachments, and are produced with an off-the-shelf polymer material.
接下來我將談談我們在 7 月宣布與 SmileDirectClub 就新興的「醫師主導居家矯正器」市場所簽訂的供應協議。我們與 SmileDirectClub 的協議是為簡單病例製造非 Invisalign 的矯正器;此類病例包含最多 20 副矯正器組合、不含 IPR 附件,並使用現成的聚合物材料生產。
On October 15, we began accepting cases from SDC, and subsequently started manufacturing aligners. We also recently implemented be Invisalign referral process for sending patients, whose case falls outside the scope of the agreed-upon SDC protocols, to Invisalign providers, and began scheduling Invisalign consultation appointments. While this is still early, we are pleased with our initial progress, and remain excited about the untapped opportunity to help provide access to treatment for consumers who wouldn't otherwise seek orthodontic treatment.
10 月 15 日,我們開始接受來自 SDC 的病例,並隨後開始製造矯正器。我們近期也導入 Invisalign 轉介流程,將超出雙方約定之 SDC 規範範圍的患者轉介至 Invisalign 提供者,並開始安排 Invisalign 諮詢門診。雖然仍在早期階段,我們對初步進展感到滿意,並持續看好這項尚未充分開發的機會,協助讓原本不會尋求齒顎矯正治療的消費者也能取得治療。
With that, I will now turn the call over to David.
接下來,我把電話交給 David。
David White - CFO
David White - CFO
Thanks, Joe. Let's review our third-quarter financial results. Total company revenue for the third quarter was $278.6 million, up 3.4% from the prior quarter, and up 34.2% from the corresponding quarter a year ago. Third-quarter Clear Aligner revenue of $243.7 million was flat sequentially, reflecting a slight increase in Clear Aligner volumes.
謝謝,Joe。我們來回顧第三季的財務結果。公司第三季總營收為 2.786 億美元,較前一季成長 3.4%,較去年同期成長 34.2%。第三季透明矯正器(Clear Aligner)營收為 2.437 億美元,較前一季持平,反映透明矯正器出貨量小幅增加。
Our year-over-year revenue growth of 22.9% reflected Invisalign case volume growth across all customer channels and geographies, as well as our price increase in international markets. Note that this past July marks a full year since we implemented the additional liner policy, and therefore, our year-over-year comparisons no longer reflects the impact from this policy change. That said, our results still, however, reflect the impact from the grandfathered cases that were under the previous policy.
我們年增 22.9% 的營收成長,反映 Invisalign 病例量在所有客戶通路與各地區的成長,以及我們在國際市場的提價。請注意,今年 7 月距離我們實施額外牙套政策已滿一年,因此,我們的年對年比較已不再反映該政策變更的影響。儘管如此,我們的結果仍反映先前政策下既有(grandfathered)病例所帶來的影響。
Q3 ASP's were flat from Q2 at about $1,285, reflecting a slightly higher mix of full and teen product, the partial impact of an international price increase, which were offset by several factors, including higher product discounts. On a year-over-year basis, Q3 ASP's were up $26, primarily due to a price increase this year, partially offset by higher product discounts.
第三季 ASP 與第二季持平,約為 1,285 美元,反映全套與青少年產品組合略為提高、國際提價的部分影響,但被多項因素(包括較高的產品折扣)所抵銷。以年對年來看,第三季 ASP 增加 26 美元,主要由今年的提價所致,但部分被較高的產品折扣所抵銷。
For the third quarter, total Invisalign shipments of [177,008] cases were flat sequentially, reflecting growth from our North American Ortho's and APAC region, offset by seasonally -- by seasonality across North American GPs and the EMEA region. Year-over-year case volume growth was 20.5%, driven by growth across all regions.
第三季 Invisalign 總出貨量為 [177,008] 例,與前一季持平,反映北美矯正專科與亞太地區的成長,但被北美一般牙醫與 EMEA 地區的季節性因素所抵銷。年對年病例量成長為 20.5%,由各地區的成長所帶動。
For North American orthodontists, Q3 Invisalign case volumes was up 3.8% sequentially and up 18.2% year-over-year. For North American GP dentists, case volume was down 2.7% sequentially and up 9.8% year-over-year. For international doctors, Invisalign case volume was down 0.5% sequentially and up 33.8% year-over-year, reflecting continued expansion of our customer base as well as increased utilization.
就北美矯正專科醫師而言,第三季 Invisalign 病例量較前一季成長 3.8%,年對年成長 18.2%。就北美一般牙醫(GP)而言,病例量較前一季下降 2.7%,年對年成長 9.8%。就國際醫師而言,Invisalign 病例量較前一季下降 0.5%,年對年成長 33.8%,反映我們客戶基礎持續擴張以及使用率提升。
Worldwide Invisalign utilization in Q3 was 5.0 cases per doctor, up from 4.7 in Q3 last year. North America Ortho utilization was a record 11.1, up from 9.9 in the prior year. North America GP utilization was 3.0, slightly up from 2.9 in the prior year. And international utilization was 4.9, up from 4.6 cases per doctor in Q3 last year, driven primarily by increased utilization in EMEA.
第三季全球 Invisalign 使用率為每位醫師 5.0 例,高於去年第三季的 4.7。北美矯正專科使用率創新高達 11.1,高於前一年的 9.9。北美一般牙醫使用率為 3.0,較前一年的 2.9 略增。國際使用率為 4.9,高於去年第三季每位醫師 4.6 例,主要由 EMEA 地區使用率提升所帶動。
In Q3, we added 2,615 new Invisalign doctors worldwide, 1,300 of which were new North American doctors and 1,315 of which were new international doctors. This compares to 2,885 in Q2 and 2,260 in the same quarter last year. Our scanner and services revenues for the third quarter was $34.9 million, up 34.7% sequentially and up 273.7% year-over-year.
第三季我們在全球新增 2,615 位 Invisalign 醫師,其中 1,300 位為新增北美醫師,1,315 位為新增國際醫師。相較之下,第二季為 2,885 位,去年同期為 2,260 位。第三季我們的掃描器與服務營收為 3,490 萬美元,較前一季成長 34.7%,年對年成長 273.7%。
Moving on to gross margin, third-quarter overall gross margin was 75.1%, down 1.1 point sequentially and down 0.8 points year-over-year, both primarily attributable to a larger percentage of scanner and services revenue, which carries a lower margin than Clear Aligner. Clear Aligner gross margin for the third quarter was 77.7%, down 0.9 points sequentially and down 1.1 point year-over-year.
接著談毛利率,第三季整體毛利率為 75.1%,較前一季下降 1.1 個百分點,年對年下降 0.8 個百分點,兩者主要皆因掃描器與服務營收占比提高,而其毛利率低於透明牙套(Clear Aligner)。第三季透明牙套毛利率為 77.7%,較前一季下降 0.9 個百分點,年對年下降 1.1 個百分點。
The sequential decrease was primarily driven by a higher number of aligners per case, partially offset by seasonally lower training. The year-over-year gross margin decrease was primarily driven by a higher number of aligners per case, partially offset by higher worldwide ASP.
毛利率的季減主要由每病例牙套數量增加所致,部分被季節性較低的訓練成本所抵銷。毛利率的年減主要同樣由每病例牙套數量增加所致,部分被全球 ASP 較高所抵銷。
Q3 gross margin for our scanner segment was a record 57.1%, up 3.5 points sequentially and 42.4 points year-over-year. Both the sequential and year-over-year increases in gross margin were primarily a result of higher ASP's and the lower manufacturing costs of our iTero element scanner relative to its prior version.
第三季我們掃描器部門毛利率創新高達 57.1%,較前一季提高 3.5 個百分點,年對年提高 42.4 個百分點。無論季增或年增,毛利率提升主要來自 ASP 較高,以及我們 iTero element 掃描器相較前一版本具有較低的製造成本。
Q3 operating expenses were $147.1 million, up sequentially by $7 million or 5%, primarily due to payroll and other costs related to increased headcount; higher depreciation, as we started to depreciate our newly implemented ERP system; as well as post-go-live support costs, but those should be decreasing over the short-term.
第三季營業費用為 1.471 億美元,較前一季增加 700 萬美元或 5%,主要由於人員擴編帶來的薪資與其他成本增加;此外,我們開始對新導入的 ERP 系統提列折舊,並產生上線後支援成本,但這些成本在短期內應會下降。
On a year-over-year basis, Q3 operating expenses were up $27.6 million or 23.1%, reflecting increased headcount and continued investment in our go-to-market activities incidental to the growth of the business. Our third-quarter operating margin was 22.3%, down 1.9 points sequentially and up 4 points year-over-year.
以年對年來看,第三季營業費用增加 2,760 萬美元或 23.1%,反映人員增加,以及隨著業務成長而持續投入市場推廣(go-to-market)活動。第三季營業利益率為 22.3%,較前一季下降 1.9 個百分點,年對年上升 4 個百分點。
The sequential decrease in operating margin relates primarily to slightly lower Clear Aligner gross margins; a higher mix of scanner revenue, which, while mentioned achieved record performance, carries a lower gross margin; as well as higher operating expenses. On a year-over-year basis, increased operating margin primarily reflects lower operating expenses as a percentage of revenue, due to volume leverage achieved on our year-over-year growth.
營業利益率的季減主要與透明牙套毛利率略降有關;掃描器營收占比提高(雖如前所述表現創新高,但其毛利率較低);以及營業費用增加。以年對年來看,營業利益率提升主要反映營業費用占營收比重下降,係因年對年成長帶來的規模槓桿效益。
With regards to our third-quarter tax provision, our tax rate was 18.4% compared to 23.2% in Q2 2016. Our Q3 tax rate was lower by approximately 5 points due to a one-time benefit from our new international corporate structure, which we implemented in conjunction with our ERP. Commencing in the third quarter, we also began including our relationship with SmileDirectClub in our reported results pure. While we didn't actually commence shipping product to them until the current quarter, our equity investment in SDC requires that we report our proportionate share of their losses.
關於第三季所得稅費用,我們的稅率為 18.4%,相較 2016 年第二季的 23.2%。第三季稅率約低 5 個百分點,係因我們新的國際公司架構帶來一次性利益;該架構係配合 ERP 導入而實施。自第三季起,我們也開始將與 SmileDirectClub 的關係納入我們所報告的結果中。雖然我們實際上直到本季才開始對其出貨,但我們對 SDC 的股權投資要求我們按比例認列其虧損。
Our share of that loss is reported below operating margin and our tax provision, and is entitled Equity and Losses of Investee. This Q3 loss, net of tax, was approximately $0.5 million. Third-quarter diluted earnings-per-share was $0.63 compared to $0.62 reported in Q2, and $0.34 reported in the same quarter last year.
我們分攤的該項虧損列示於營業利益率與所得稅費用之下,科目名稱為「被投資公司權益與損失」(Equity and Losses of Investee)。第三季該項虧損(稅後)約為 50 萬美元。第三季稀釋後每股盈餘為 0.63 美元,相較第二季的 0.62 美元,以及去年同期的 0.34 美元。
Moving on to the balance sheet. For the third quarter, our Accounts Receivable balance was $245 million, up approximately 27% sequentially. Our overall DSO was 78 days, up 14 days sequentially and year-over-year, as a result of our new ERP system and other related systems that impacted the timing of some of our customer collections. We would anticipate that our DSOs will remain above our historical average for several quarters as we work through these changes.
接著看資產負債表。第三季應收帳款餘額為 2.45 億美元,較前一季約增加 27%。整體 DSO 為 78 天,較前一季及去年同期皆增加 14 天,係因我們新的 ERP 系統及其他相關系統影響部分客戶收款時點。我們預期在處理這些變更的數個季度內,DSO 將維持高於歷史平均水準。
Capital expenditures for the third quarter were $17.3 million, primarily related to equipment purchases to expand our manufacturing capacity in Juarez, Mexico and, to a lesser extent, our ERP implementation. Cash flow from operations for the third quarter was $59.8 million, and free cash flow for the third quarter, defined as cash flow from operations less capital expenditures, amounted to $42.5 million.
第三季資本支出為 1,730 萬美元,主要與設備採購有關,用以擴充墨西哥華雷斯(Juarez)的製造產能,另有較小部分與 ERP 導入相關。第三季營運活動現金流為 5,980 萬美元;第三季自由現金流(定義為營運活動現金流減資本支出)為 4,250 萬美元。
During the quarter, we concluded our previously announced $50 million accelerated stock repurchase with final delivery of 143,310 shares, and purchased an additional 88,000 shares amounting to $8.2 million in open market repurchases. These repurchases were collectively part of a three-year $300 million stock repurchase program announced on April 23, 2014.
本季度內,我們完成先前公告的 5,000 萬美元加速股票回購(ASR),最終交付 143,310 股,並在公開市場額外回購 88,000 股,金額為 820 萬美元。上述回購合計皆屬於 2014 年 4 月 23 日宣布之三年期 3 億美元股票回購計畫的一部分。
In addition to the April 2014 repurchase plan, Align also announced on April 28 of this year a new plan to repurchase up to an additional $300 million of the Company stock. There remains approximately $341.8 million available for repurchases under these two existing stock repurchase authorizations.
除 2014 年 4 月的回購計畫外,Align 亦於今年 4 月 28 日宣布一項新計畫,將再回購最多額外 3 億美元的公司股票。在這兩項既有股票回購授權下,目前仍有約 3.418 億美元可供回購。
Cash, cash equivalents and marketable securities, including both short and long-term investments, were $675.8 million. This compares to $678.7 million at the end of 2015, a decrease of approximately $2.9 million. Of our $675.8 million in cash, cash equivalents and marketable securities, $288.3 million was held by the US, and $387.5 million was held by our international entities.
現金、約當現金及有價證券(包含短期與長期投資)為6.758億美元。相較於2015年底的6.787億美元,約減少2,900萬美元。在我們6.758億美元的現金、約當現金及有價證券中,2.883億美元由美國持有,3.875億美元由我們的國際實體持有。
Our US balances were up $107 million quarter-over-quarter, of which $147 million was contributed as a result of implementing our new international corporate structure, which was then reduced by our investment in SDC of about $47 million. As of September 30, 2016, the balance of our equity method investments for SmileDirectClub was $46.3 million.
我們的美國餘額較上一季增加1.07億美元,其中1.47億美元係因導入新的國際公司架構而挹注,之後再因我們對SDC約4,700萬美元的投資而減少。截至2016年9月30日,我們對SmileDirectClub之權益法投資餘額為4,630萬美元。
With that, let's now turn to our business outlook and the factors that inform our view, starting with the demand outlook. As Joe mentioned in his comments, our incoming case receipts in North America in Q3 were slower than we had originally anticipated. And given that our targeted turnaround time to our customers, we ship much of our backlog as of quarter-end.
接下來,我們來談談業務展望以及影響我們觀點的因素,先從需求展望開始。如Joe在評論中提到,我們北美地區第三季的新進病例收件量比原先預期更慢。並且考量我們對客戶的目標周轉時間,我們在季末時已出貨了相當多的積壓訂單。
Since then, our case receipts in North America have improved and returned to a year-over-year growth rate early in the quarter that is well ahead of both our second and third-quarter performance. As such, for -- our outlook for Q4 appears solid. However, lower Q3 case receipts and less backlog will dampen our Q4 shipment growth rate as our backlog begins to naturally return to normal levels.
自那之後,我們北美地區的病例收件量已改善,並在本季初回到年增率成長,且明顯優於第二季與第三季的表現。因此,我們對第四季的展望看起來穩健。然而,第三季較低的病例收件量以及較少的積壓訂單,將在積壓訂單自然回到正常水位的過程中,抑制第四季的出貨成長率。
As such, our Q4 guidance reflects this impact. On a longer-term basis, we remain confident that our Invisalign revenue growth on a full-year basis will be within the upper half of our long-term model range of 15% to 25%.
因此,我們的第四季指引已反映此影響。從較長期來看,我們仍有信心,Invisalign全年營收成長將落在我們長期模型區間15%至25%的上半段。
With that backdrop, for our international markets, Invisalign demand remained strong, and we would expect Invisalign volume in Q4 to be up sequentially, driven by growth in EMEA coming off a seasonally slower summer period. APAC is usually seasonally down sequentially coming off a strong summer.
在此背景下,就國際市場而言,Invisalign需求仍然強勁,我們預期第四季Invisalign出貨量將較前一季增加,主要由EMEA在季節性較慢的夏季過後所帶動的成長所驅動。APAC通常在強勁的夏季過後,會呈現季節性較前一季下滑。
For North America, we would expect North America Invisalign volumes in Q4 to be flat, primarily as a result of the factors I just described. For our scanner business, we expect scanner shipments to be up sequentially as the iTero Element continues to penetrate the market.
就北美而言,我們預期北美第四季Invisalign出貨量將持平,主要是我剛才描述的因素所致。就我們的掃描器業務而言,隨著iTero Element持續滲透市場,我們預期掃描器出貨量將較前一季增加。
With this as a backdrop, we expect the fourth quarter to shape up as follows. Invisalign case volume is anticipated to be in the range of [182,500] to [184,500] cases, up approximately 15% over the same period a year ago, reflecting continued strong growth from international but muted by the factors just described.
在此背景下,我們預期第四季將如下發展。Invisalign病例量預計介於[182,500]至[184,500]例,較去年同期約成長15%,反映國際市場持續強勁成長,但受到前述因素的抑制。
We expect Q4 net revenues to be in the range of $289.2 million to $293.9 million, an increase of 27.6% year-over-year and well above our long-term target of 15% to 25%. We expect Q4 gross margin to be in the range of 74.7% to 75.1%, essentially flat sequentially, primarily due to an increased mix of scanner business, and lower margins and slightly lower Clear Aligner ASP's.
我們預期第四季淨營收介於2.892億美元至2.939億美元,年增27.6%,且明顯高於我們15%至25%的長期目標。我們預期第四季毛利率介於74.7%至75.1%,與前一季基本持平,主要因掃描器業務占比提高,以及透明矯正器(Clear Aligner)毛利較低且平均售價(ASP)略低。
We expect Q4 operating expenses to be in the range of $149.6 million to $150.6 million, up quarter-over-quarter, primarily due to increased headcount offset by seasonally less advertising and lower ERP post-go-live support costs. Q4 operating margin should increase sequentially and be in the range of 23.0% to 23.9%. Our effective tax rate should be approximately 22%.
我們預期第四季營業費用介於1.496億美元至1.506億美元,較前一季增加,主要因人力增加,部分被季節性較少的廣告支出及ERP上線後支援成本降低所抵銷。第四季營業利益率應較前一季提升,介於23.0%至23.9%。我們的有效稅率應約為22%。
We estimate the Q4 impact of the SmileDirectClub transaction will reduce diluted EPS by less than $0.01 per share, and diluted shares outstanding should be approximately [$81.5 million], exclusive of any share repurchases. Taken together, we expect our Q4 diluted EPS to be in a range of $0.64 to $0.67.
我們估計SmileDirectClub交易對第四季的影響,將使稀釋後每股盈餘(EPS)減少不到每股0.01美元,而流通在外稀釋後股數應約為[8,150萬股],不含任何庫藏股回購。綜合以上,我們預期第四季稀釋後EPS介於0.64美元至0.67美元。
Before I turn the call back over to Joe, I want to say a few things about my decision to retire and spend more time with my family. This is something my wife Nikki and I have thought about and planned for some time and communicated to Joe. This timing has afforded Joe and the Board time to find a replacement for me before I step down. I want to thank many of you who I have worked with and come to know well over the past few years. It has been a pleasure working for such a great Company, and I feel honored to have been a part of history in the making, as we transform and modernize the orthodontic industry.
在我把電話交回給Joe之前,我想談幾點關於我決定退休並花更多時間陪伴家人的原因。這是我和太太Nikki思考並規劃了一段時間的事情,也已與Joe溝通。這個時點也讓Joe與董事會在我卸任前,有時間為我找到接任者。我要感謝過去幾年與我共事、並逐漸熟識的許多人。能在這麼優秀的公司工作是一種榮幸;在我們推動轉型並使齒顎矯正產業現代化的過程中,能成為這段歷史的一部分,我也深感榮耀。
But it's not time to say goodbye just yet. Although John will start this week, and I will hand over formal CFO responsibilities immediately, I will work closely with him in the coming months, and you will see us together at upcoming financial conferences and industry meetings.
但現在還不是道別的時候。雖然John將於本週開始任職,而我也會立即移交正式的財務長(CFO)職責,但接下來幾個月我會與他密切合作,你們也會在即將到來的財務研討會與產業會議上看到我們一同出席。
Until then, let's turn the time to Joe for his closing comments, and then open the call up for your questions.
在此之前,讓我們把時間交給Joe做結語,接著開放各位提問。
Joe Hogan - President, CEO and Director
Joe Hogan - President, CEO and Director
Thanks, David. Overall, I'm pleased with our Q3 results, especially the continued strength from our EMEA and APAC regions. Notwithstanding weaker-than-expected North American case receipts in Q3, our business remains solid and on track. Based on the high end of our Q4 guidance, the implied full-year results will be significantly higher than our original outlook provided in January, with 28% revenue growth, 20% Clear Aligner volume growth, and 23% operating margins.
謝謝你,David。整體而言,我對第三季的結果感到滿意,尤其是EMEA與APAC地區持續展現強勁動能。儘管第三季北美病例收件量弱於預期,我們的業務仍然穩健且按計畫推進。以我們第四季指引的高端來看,推算的全年結果將顯著高於我們1月提供的原始展望,包括營收成長28%、透明矯正器(Clear Aligner)出貨量成長20%,以及營業利益率23%。
We have a huge opportunity in front of us to replace wires and brackets and transform the orthodontic market. As we continue to execute on our strategic plans, I'm confident in our ability to outpace the market and achieve revenue growth for 2016 and beyond at the upper end of our target of 15% to 25%. Looking forward to following up with many of you in the coming weeks at various conference and industry meetings.
我們面前有巨大的機會,以透明矯正取代鋼線與托槽,並改造齒顎矯正市場。隨著我們持續執行策略計畫,我有信心我們能超越市場表現,並在2016年及未來,達成位於15%至25%目標區間上緣的營收成長。期待在接下來幾週於各項研討會與產業會議上,與各位中的許多人再進一步交流。
I'll now open the call to your questions. Operator?
我現在開放各位提問。接線員?
Operator
Operator
(Operator Instructions) Steve Beuchaw, Morgan Stanley.
(接線員指示)Steve Beuchaw,Morgan Stanley。
Jack Lasday - Analyst
Jack Lasday - Analyst
This is Jack on for Steve. Just a question looking at the trends in the business. Clearly, the scanner business is doing very well. The aligner franchise not going quite as strongly as we thought into 4Q, obviously, with some of the weakness in North America. But I'm wondering if there's anything going on with the sales force, and if there is a bandwidth issue at all there, with scanners drawing so much attention? Thanks.
我是Jack,代替Steve發問。我有個問題,想從業務趨勢來看。顯然,掃描器業務表現非常好。而透明矯正器業務進入第四季的動能沒有我們原先想得那麼強,顯然北美有些疲弱。但我想知道,銷售團隊是否有任何狀況?是否存在任何產能/帶寬問題,因為掃描器吸引了太多注意力?謝謝。
Joe Hogan - President, CEO and Director
Joe Hogan - President, CEO and Director
Hey, Jack, it's Joe. I would say the definitive answer to your question is absolutely not. I mean we obviously watch that closely to make sure that we primarily focus on where the focus needs to be by sales rep.
嗨,Jack,我是Joe。我會說,你這個問題的明確答案是:絕對沒有。我的意思是,我們當然會密切關注這點,以確保銷售代表的重點主要放在需要聚焦的地方。
And I'd also just take a difference with your initial comment, is I think the overall liner market continues to be strong. We had a little bit of a speed bump in third quarter from an orders standpoint. It's mainly GP -- low submitting GPs that we've talked about before. But overall, in the forecast that we've given you for fourth quarter, and fortunately, given the timing of the call today, we get a good clear October look. We are very confident to be on the upper end of our 15% to 25% revenue growth that we've been indicating over the last 18 months or so.
另外,我也想對你一開始的說法稍作不同看法:我認為整體透明矯正器市場仍然強勁。從訂單角度來看,我們第三季遇到了一點小波折。主要是我們之前談過的GP——提交量較低的一般牙醫。但整體而言,依我們給各位的第四季預測,而且也很幸運因為今天電話會議的時間點,我們能清楚看到10月的表現。我們非常有信心,能達到過去約18個月來一直所提到的15%至25%營收成長區間的上緣。
Jack Lasday - Analyst
Jack Lasday - Analyst
Okay that's good. And just on the one-week aligner policy that you introduced about a month ago, just curious what doctor uptake has been like so far? And how quickly you might expect that to start to become the norm? And I'll hop back into queue. Thanks.
好的,那很好。另外,關於你們大約一個月前推出的一週配戴矯正器政策,我只是好奇目前醫師的採用情況如何?以及你們預期多快會開始成為常態?我會回到等候隊列。謝謝。
Joe Hogan - President, CEO and Director
Joe Hogan - President, CEO and Director
Well, you know, as we mentioned in the release, many doctors were already experimenting or were actually utilizing one-week wear, not just in North America, but all over the world. So many have discontinued with what they were doing.
嗯,你知道,正如我們在新聞稿中提到的,許多醫師其實早就在嘗試或已經在使用一週配戴,不僅在北美,而是在全球各地。所以很多人已經停止了他們原本的做法。
Overall, we've had a very positive response. Again, this is -- we leave this in a doctor's hands. There are some cases we don't think -- a majority of cases at all -- they might have to move to two weeks at some point in time. But we feel, by far, the majority of our cases can go with one-week wear, with very -- a lot of confidence in the teens market also, in the sense that their dentition being looser and being able to be able to move more quickly.
整體而言,我們收到非常正面的回應。再次強調,這件事——我們把決定權交在醫師手上。有些案例我們認為——其實不是大多數案例——他們可能在某個時間點需要改回兩週。但我們相信,絕大多數的案例都可以採用一週配戴,而且——我們也對青少年市場很有信心,因為他們的齒列較鬆、也能更快移動。
So, I'm -- we're not predicting an immediate surge in orders based on one-week wear, but we think it's just another aspect of our go-to-market, it makes Invisalign very enticing for patients versus wire and brackets. Okay, Jack?
所以,我——我們並不預期因為一週配戴就會立刻出現訂單激增,但我們認為這只是我們市場推進策略的另一個面向,讓 Invisalign 相較於鋼絲與托槽對患者更具吸引力。好的,Jack?
Jack Lasday - Analyst
Jack Lasday - Analyst
That's perfect. Yes. Thanks.
太好了。是的。謝謝。
Joe Hogan - President, CEO and Director
Joe Hogan - President, CEO and Director
Yes. Thank you.
是的。謝謝你。
Operator
Operator
Steven Valiquette, Bank of America Merrill Lynch.
Steven Valiquette,美國銀行美林。
Steven Valiquette - Analyst
Steven Valiquette - Analyst
Congrats on these strong results. Hey, so I guess just for us, the comment about the Q4 shipments, growth rate, and you are reflecting the backlog beginning to return to normal levels. Just curious to make sure that that should work itself through in the fourth quarter such that if the strong volume you saw in October carries over into early next year, that we should mechanically then obviously see some improvement in the year-over-year growth as we go into early 2017. Is that the right way to think about that?
恭喜這些強勁的業績。嘿,所以我想就我們而言,關於第四季出貨量、成長率的評論,以及你們反映積壓訂單開始回到正常水準。我只是想確認,這應該會在第四季消化完,這樣如果你們在十月看到的強勁量能延續到明年初,那麼從機制上我們顯然就會在進入 2017 年初時看到年對年成長有所改善。這樣理解對嗎?
Joe Hogan - President, CEO and Director
Joe Hogan - President, CEO and Director
Steve, just back up one. Yes, we expect that to stabilize in the fourth quarter. That's why we call the shipment rates that we've been calling for you too. If I interpret the second part of your question is, as we move into 2017, should we be on a stronger footing in a sense of a backlog -- that's our plan.
Steve,我先退一步說。是的,我們預期第四季會趨於穩定。這也是為什麼我們會給你們我們一直在提的出貨率指引。如果我理解你問題的第二部分是:當我們進入 2017 年時,是否應該在積壓訂單方面處於更穩健的狀態——那是我們的計畫。
Steven Valiquette - Analyst
Steven Valiquette - Analyst
Okay, so the backlog would not extend beyond one quarter basically, that's what I was trying to clarify. So sorry for the poor wording the first time around.
好的,所以積壓訂單基本上不會延續超過一個季度,這就是我想釐清的。抱歉我第一次措辭不太好。
Joe Hogan - President, CEO and Director
Joe Hogan - President, CEO and Director
Correct, Steve. It will naturally return to its nominal levels this quarter as our case volumes recover, case receipt volumes recover, and as we are seeing early in the quarter so far.
沒錯,Steve。隨著我們的病例量回升、病例收件量回升,而且就我們目前在本季初看到的情況,積壓訂單會在本季自然回到其名目水準。
Steven Valiquette - Analyst
Steven Valiquette - Analyst
Okay, got it. Okay, all right, great. Thanks.
好的,了解。好,好,太好了。謝謝。
Joe Hogan - President, CEO and Director
Joe Hogan - President, CEO and Director
Thanks, Steve.
謝謝,Steve。
Operator
Operator
Brandon Couillard, Jefferies.
Brandon Couillard,Jefferies。
Brandon Couillard - Analyst
Brandon Couillard - Analyst
Joe or David, as we think about the economic sensitivity of the Clear Aligner business, to what extent do you think we've seen any of that sort of lead over into the Ortho channel? And not wanting to really split hairs here, but EMEA growth slowed a little bit sequentially. To what extent, if at all, have you seen any, I guess, economic effects there in the core Western Europe market, if at all?
Joe 或 David,當我們思考透明矯正器業務對經濟景氣的敏感度時,你們認為這種影響在多大程度上已經外溢到矯正(Ortho)通路?我不想在這裡過度吹毛求疵,但 EMEA 的成長率在序列上稍微放緩。在核心西歐市場,你們是否、以及在多大程度上看到任何經濟面的影響(如果有的話)?
Joe Hogan - President, CEO and Director
Joe Hogan - President, CEO and Director
You know, I wouldn't -- I'll let David join in on this too -- I wouldn't call these any macroeconomic effects as far as what we are seeing right now. Your comment about it bleeding over into Ortho, we had record utilization rates in Ortho, up significantly. I think it's 9.9 to 11.1 in the quarter, so it shows terrific or continued growth in Ortho utilization with our product line.
你知道,我不會——我也會讓 David 一起補充——就我們目前看到的情況而言,我不會把這稱為任何總體經濟影響。你提到是否外溢到 Ortho,我們在 Ortho 的使用率創下新高,顯著上升。我想本季是從 9.9 到 11.1,所以顯示我們產品線在 Ortho 的使用率有非常亮眼或持續的成長。
So we feel broadly this is a GP blip. This has been talked about in the marketplace in the third quarter that we saw in North America across the board, not just with Invisalign but with the dental market in general. So -- but again, our October order rates indicate that we are on track with the kind of growth we experienced in the second quarter of this year. And we think that will continue.
所以我們整體認為這是 GP(一般牙科)的一個短暫波動。市場在第三季就有討論到,我們在北美看到的是全面性的情況,不只是 Invisalign,而是整體牙科市場也是如此。所以——但再次強調,我們十月的訂單率顯示,我們正朝著今年第二季所經歷的那種成長軌跡前進。而且我們認為這會持續。
David, go ahead.
David,你來補充。
David White - CFO
David White - CFO
Yes, Brandon, just to add a little color to that, we -- when we look at our GP doctors by segment in terms of the case volume that they do, the doctors that are fully engaged with Invisalign, and have incorporated it into their practices, are typically less susceptible to softness in the market, because their practice has been built really around the -- or Invisalign has become such an integral part of their practice that they typically are on the offense in terms of business development.
好的,Brandon,我再補充一點背景,我們——當我們按 GP 醫師的分群來看他們的病例量時,那些完全投入 Invisalign、並已把它納入其診所營運的醫師,通常較不容易受到市場疲弱的影響,因為他們的診所基本上是圍繞著——或者說 Invisalign 已成為其診所非常核心的一部分,因此他們在業務開發上通常是採取更積極進攻的姿態。
It's really more the lower-tier doctors that are still quite dabbling in Invisalign, haven't quite changed their practice flows and so forth. And so when we see an overall softening in the market, it tends to be those doctors that tend to be the first to pull back. And when we look at the Q3, that's precisely where we saw it -- really those doctors that are at the lower volume levels.
真正比較會受影響的是較低層級的醫師,他們仍然只是偶爾嘗試 Invisalign,還沒有真正改變他們的診所流程等等。因此當我們看到整體市場轉弱時,往往是這些醫師最先縮手。而當我們回頭看第三季,確實就是在那裡看到——主要是那些病例量較低的醫師。
Brandon Couillard - Analyst
Brandon Couillard - Analyst
Then one more for you, David. In terms of the operating cash flow and the DSO build in the period, why would it necessarily take several quarters for that to normalize?
那再問你一題,David。就本期營運現金流以及 DSO(應收帳款週轉天數)上升而言,為什麼它一定需要好幾個季度才會正常化?
David White - CFO
David White - CFO
Well, I hope it won't. You know, we had a very successful implementation in July. We did have some delays in invoicing, a few customers, and we're working through those right now, and expect to have those worked out. When we sell to 30,000-plus customers at a time, it doesn't take very many to create -- to influence that DSO.
嗯,我希望不會。你知道,我們在七月的導入非常成功。確實有少數客戶的開立發票出現一些延遲,我們正在處理,並預期會把這些問題解決。當我們同時對 30,000 多名客戶銷售時,其實不需要很多客戶就會造成——就會影響到 DSO。
And one of the things with most customers is when a sales tax rate or a VAT rate is incorrect, you typically wind up having to rebuild the customer at the correct VAT rate or sales tax rate, and then the clock starts all over again. And so, we are generally up against that issue right there. And we think over the next couple of quarters, it will be behind us.
而且對多數客戶而言,當銷售稅率或增值稅(VAT)稅率不正確時,通常你最後必須以正確的 VAT 稅率或銷售稅率重新建立該客戶資料,然後帳期就得重新開始計算。所以我們基本上正面臨的就是這個問題。我們認為在接下來幾個季度內,這件事就會過去。
Brandon Couillard - Analyst
Brandon Couillard - Analyst
Thanks.
謝謝。
Operator
Operator
Jon Block, Stifel.
Jon Block,Stifel。
Jon Block - Analyst
Jon Block - Analyst
Two questions. The first one has got two parts, just one for Joe and David. So just to begin SDC, Joe, maybe if you can tell us what has been sort of the Invisalign provider reaction to date? Anything surprise you on either the positive or negative side?
兩個問題。第一個問題有兩個部分,分別問 Joe 和 David。先從 SDC 開始,Joe,也許你可以跟我們說一下,到目前為止 Invisalign 供應端(provider)的反應如何?有沒有任何讓你驚訝的地方,不論是正面或負面?
And the second part to that question is for David. Anything in the 4Q 2016 revenue guidance on SDC? Since I believe, as you mentioned, they will be shipping cases for the vast majority of the quarter. And then I've just got a quick follow-up. Thanks.
而這個問題的第二部分是問 David。2016 年第四季營收指引中,有沒有納入任何與 SDC 相關的內容?因為我相信,如你所提到的,他們在本季絕大多數時間都會出貨病例。然後我還有一個簡短的追問。謝謝。
Joe Hogan - President, CEO and Director
Joe Hogan - President, CEO and Director
Hey, Jon, it's Joe. Look, I think the provider -- honestly, the provider reaction to this was anticipated. I think you picked it up in your analysis too with the 100 or so that you do. Many orthodontists aren't happy with this. Many of them understand why we did it.
嗨,Jon,我是 Joe。你看,我認為供應端——老實說,供應端對這件事的反應是在預期之內。我想你在你的分析裡也有捕捉到,你大概訪談了 100 位左右。很多矯正專科醫師對此不高興。也有很多人理解我們為什麼要這麼做。
I think they feel good about it not being Invisalign, that it is a -- it's the X-30 and it's a lift-row kind of a system and not a gingerbread cut. But it's just really a complete offtake of what the product that they were using before.
我認為他們對於它不是 Invisalign 這件事感覺良好,因為它是——它是 X-30,而且是一種 lift-row 類型的系統,而不是那種薑餅式切割。但它其實就是對他們之前使用的那個產品的完整替代。
So I think overall, I haven't been surprised with the reaction. We haven't seen a response in the market that would be negative in some way. We're sitting here at the Ortho Summit, so we'll get an on-the-ground feel here this week. But I would say overall good, because I think, frankly, there is an understanding in the marketplace of what we did and how we did this.
所以我認為整體而言,我對這個反應並不意外。我們沒有看到市場上有任何可能在某種程度上偏負面的回應。我們現在人在 Ortho Summit,所以這週我們會在第一線感受一下。但我會說整體是好的,因為我認為,坦白說,市場對於我們做了什麼以及我們如何做到這件事是有理解的。
That doesn't mean there's not a lot of passion about a doctor-directed kind of virtual model that exists out there. But we feel the response has been in line with what we had anticipated.
這並不代表外界對於一種由醫師主導的虛擬模型沒有很強烈的熱情。但我們覺得回應符合我們原先的預期。
David White - CFO
David White - CFO
And John, to your second part of the question, really SDC didn't really impact any of our thinking as it relates to the Q4 guidance. When you look at our year-over-year growth that we're -- that has been baked into our guidance, it really comes to two factors -- one, which has to do with a renormalization of our backlog, if you call it that, coming off of Q3, a weaker case in receipts.
而 John,關於你問題的第二部分,SDC 其實並沒有影響我們在 Q4 指引相關的任何想法。當你看我們年對年成長——也就是已經納入我們指引中的成長——主要來自兩個因素:第一,是我們積壓訂單的再正常化(如果你要這麼稱呼的話),也就是從 Q3 下來,收案量較弱。
And then secondly, when you look at a year ago, Q4 of 2015, that quarter was up 25% year-over-year and up 9% quarter-over-quarter. And so it was a very -- it was just a rock solid quarter for us. And so I think when you look at the compare quarter-over-quarter, I think you are seeing a comp there that's also having some bearing on it.
第二,當你回看一年前、2015 年的 Q4,那一季年對年成長 25%,季對季成長 9%。所以那對我們來說是一個——非常——非常穩健的一季。因此我認為當你看季對季的比較時,你會看到那個比較基期也對結果有一些影響。
Jon Block - Analyst
Jon Block - Analyst
Okay. I'll follow-up with you off-line on that one, David. I guess I'm just wondering if you are recognizing revenue from shipping out the aligners. But I'll follow up with you off-line on that one.
好的。David,我會在會後再跟你私下追問那一點。我想我只是想確認你們是否是在出貨矯正器時認列營收。不過我會在會後再跟你私下追問。
The other one, I just hate to burn one on Cadent, but I do think it's important just for 2017, Joe, how do we think about the scanner? And I'm just asking because it's a very different business than Invisalign. It's capital and you're coming off of a big upgrade with Element. So just when we look at 2017, up, down, flat, specific to the Cadent business. Thanks, guys.
另外一個問題,我其實不太想把一個問題名額用在 Cadent 上,但我確實覺得對 2017 年很重要,Joe,我們該怎麼看待掃描器?我之所以問,是因為這跟 Invisalign 是非常不同的業務。它是資本設備,而且你們剛完成 Element 的一次重大升級。所以當我們看 2017 年時,就 Cadent 業務而言,是上升、下降、還是持平?謝謝各位。
Joe Hogan - President, CEO and Director
Joe Hogan - President, CEO and Director
You know, 2017, John, just to be clear, up. I'm not going to give you a percentage, but it will be up. I think you can see with our announcement with our simulator product and things we've been putting together, the scanner is really important for us in the sense of how we go to market with the Ortho's but particularly with GPs also.
John,2017 年,先講清楚,會成長。我不會給你百分比,但會成長。我想你可以從我們對模擬器產品的公告,以及我們正在整合的各項內容看出來,掃描器對我們非常重要,因為這關係到我們如何面向市場,不僅是對矯正科醫師(Ortho),尤其也包括一般牙醫(GP)。
So think about that scanner business is going up. Don't think of the margin being as dilutive as what we talked about before, as you put that in the model. Just think of it being almost equal to Invisalign in that sense.
所以把掃描器業務視為會成長。在你把它放進模型時,不要把毛利率想成像我們之前談到的那樣具有稀釋性。就把它想成在那個意義上幾乎與 Invisalign 相當。
I'm going to let David backtrack here on the SDC fourth-quarter piece and next year, so we can just clear that up now with you, John.
我先請 David 回頭補充一下關於 SDC 第四季以及明年的部分,這樣我們現在就能跟你釐清,John。
David White - CFO
David White - CFO
Yes. So back to that question, Jon, on SDC. Very minimal revenue in our outlook this quarter for SDC. We really just got off started in the middle of October. We are taking this very slowly as we integrate into their practice. So, really a minimal consideration in the revenue guidance we gave for Q4. Very small.
是的。回到你剛才關於 SDC 的問題,Jon。我們在本季展望中,來自 SDC 的營收非常少。我們其實是到 10 月中才剛開始。我們在整合進他們的診所流程時採取非常謹慎、循序漸進的方式。所以,在我們給出的 Q4 營收指引中,SDC 的考量其實非常有限。非常小。
Going back to the scanner, I just want to highlight one other thing about our scanner business. You know, here's two components to that business, one of which has to do with the sale of the hardware itself, the equipment. But then secondly, the ongoing support that we -- revenue that we recognize associated with maintenance and subscriptions and so forth, that revenue grows in proportion to our installed base.
回到掃描器,我還想強調我們掃描器業務的另一點。你知道,這個業務有兩個組成部分,其中之一是硬體本身、設備的銷售。第二則是我們所提供的持續支援——也就是我們因維護、訂閱等所認列的營收;這部分營收會隨著我們的裝機基礎(installed base)成比例成長。
And as you've seen this year, our scanner growth rate from a unit standpoint is quite significant. So the installed base is building actually quite nicely. And so that's going to be -- form a nice foundation, I think, for the scanner business going into 2017.
而如你今年所見,我們掃描器在出貨台數(unit)角度的成長率相當顯著。所以裝機基礎其實累積得相當不錯。因此我認為,這將會——為 2017 年的掃描器業務奠定一個很好的基礎。
Jon Block - Analyst
Jon Block - Analyst
Great. Thank you, guys.
很好。謝謝各位。
Joe Hogan - President, CEO and Director
Joe Hogan - President, CEO and Director
All right, Jon.
好的,Jon。
Operator
Operator
John Kreger, William Blair.
John Kreger,William Blair。
John Kreger - Analyst
John Kreger - Analyst
Joe, maybe following up on Jon's question, any other 2017 comments that you'd care to give us? You are certainly coming up against some very tough comps in terms of the Invisalign unit growth. Thanks.
Joe,或許延續 Jon 的問題,你還有沒有其他關於 2017 年的看法願意提供?你們在 Invisalign 出貨量成長方面,確實將面臨一些非常艱難的比較基期。謝謝。
Joe Hogan - President, CEO and Director
Joe Hogan - President, CEO and Director
John, no, I'd prefer not to give any more 2017 comments, but I think you can tell from my comments we are optimistic about 2017, and believe this year -- I mean, obviously above guidance of what we gave you in 2016.
John,沒有,我比較不想再提供更多 2017 年的評論,但我想你可以從我的說法看出來,我們對 2017 年是樂觀的,而且相信今年——我是說,顯然會高於我們在 2016 年給你的指引。
Our international growth has been tremendous. Our Ortho utilization numbers are good. To come out next year, we have several programs with GP in North America that we think will address some the weakness that we've experienced. Invisalign Go that we've put in place is a big one. Some of our key opinion leaders and how they go about the Ortho market -- I mean, the GP market right now has really been incredibly successful.
我們的國際成長非常強勁。我們在矯正科(Ortho)的使用率數據表現良好。展望明年,我們在北美有幾個針對一般牙醫(GP)的計畫,我們認為將能解決我們所經歷的一些疲弱。我們已經推出的 Invisalign Go 是其中一個重點。我們的一些關鍵意見領袖,以及他們在矯正市場——我是說,一般牙醫市場——的推動方式,目前確實非常成功。
Our TFM model that we are implying here in the United States, not just in the Ortho channel but the GP channel also, also gives us confidence that we can maintain that kind of momentum. But outside of that, I don't care to talk about any numbers and specifics, John.
我們在美國所推行的 TFM 模式,不僅在矯正科通路,也在一般牙醫通路,同樣讓我們有信心能維持那樣的動能。但除此之外,我不想談任何數字與細節,John。
John Kreger - Analyst
John Kreger - Analyst
Okay, great. And then just one other follow-up in terms of your comments about the slower incoming case receipts. When did you start to see that? We've heard other dental providers talking about slowdowns as early as June. Was that strictly in September? Or did you see it start earlier in the summer?
好的,很好。另外再追問一點,關於你提到收案量(incoming case receipts)放緩的評論。你們是從什麼時候開始看到的?我們聽到其他牙科供應商說,早在 6 月就出現放緩。那是只發生在 9 月嗎?還是你們在夏季更早的時候就開始看到了?
Joe Hogan - President, CEO and Director
Joe Hogan - President, CEO and Director
So, John, it really began showing itself up in early July. And at the time when we were seeing it, we were thinking it just might be early seasonality. You know, we do -- even though we know that Q3 is a seasonally weaker quarter for GPs; a seasonally stronger quarter for Ortho, particularly teens; weaker seasonally EMEA, et cetera, that seasonality is not just -- it tends to move.
John,實際上是在 7 月初開始顯現。當時我們看到時,還以為可能只是季節性提早發生。你知道,我們確實——即使我們知道 Q3 對一般牙醫(GP)而言是季節性較弱的一季;對矯正科(Ortho)而言則是季節性較強的一季,特別是青少年;而 EMEA 等地區則季節性較弱,等等——但季節性不只是——它往往會移動。
And so sometimes it will show up earlier or later. And so in early July, we thought it was more just simply an earlier seasonality. And what wound up happening was it wound up being more seasonally weak, you might say, across almost the entire quarter.
所以有時候它會提早或延後出現。因此在 7 月初,我們以為那只是單純季節性提早。但最後發生的是,你可以說,幾乎整個季度都呈現出更偏季節性疲弱的狀況。
John Kreger - Analyst
John Kreger - Analyst
Great, thanks.
太好了,謝謝。
David White - CFO
David White - CFO
Thanks, John.
謝謝你,John。
Operator
Operator
Richard Newitter, Leerink Partners.
Richard Newitter,Leerink Partners。
Richard Newitter - Analyst
Richard Newitter - Analyst
Thank you for taking the questions. Joe, just maybe one more kind of on a go-forward view without maybe giving specific additional guidance on 2017. Can you give us a little more color or at least some of the things we should be thinking about as we refine our models for 2017 on -- what puts and takes should we be considering on the cost side, whether it's mix shift, just things to bear in mind as you anniversary the ERP? Can you walk us through some of the things just to think about there?
謝謝讓我提問。Joe,我想再問一個偏向未來展望的問題,但不一定要提供 2017 年更具體的額外指引。你能否多給我們一些顏色(細節),或至少告訴我們在完善 2017 年模型時應該思考哪些事情——在成本端有哪些拉抬與抵銷因素需要考量,例如產品組合轉移,或是在 ERP 滿周年時有哪些需要留意的事項?你能帶我們走一遍,說說有哪些點值得注意嗎?
Joe Hogan - President, CEO and Director
Joe Hogan - President, CEO and Director
No, not really. (laughter) No, Richard, we -- no, we appreciate you wanting to fill out your spreadsheet for next year. We're trying to give you as broad a guidance and positive a guidance as we can, but to really start to nail those specifics wouldn't be in line with the kind of information we normally divulge.
不,還真不行。(笑聲) 不,Richard,我們——不,我們理解你想把明年的試算表填完整。我們正試著給你盡可能寬泛、也盡可能正面的指引,但若要開始把那些細節釘死,就不符合我們通常會揭露的資訊範圍。
David White - CFO
David White - CFO
Yes. When we get to the January earnings call for reporting year-end results, we'll be glad to throw some meat on the bones, so to speak, to kind of describe our outlook into the year. But suffice it to say, at this point, I think Joe's comments earlier about revenue growth and so forth in our -- above our long-term range, et cetera, should suffice.
是的。等到一月的財報電話會議、我們公布全年結果時,我們很樂意再「加點料」,也就是更具體地描述我們對新年度的展望。但就目前而言,我認為 Joe 先前對營收成長等的評論——例如高於我們長期區間等等——應該就足夠了。
Richard Newitter - Analyst
Richard Newitter - Analyst
Got it. And then maybe just to -- you put out there a confidence level to get to the kind of the upper part of your long-term range of 15% to 25%. Is that really just kind of the GP initiatives? Obviously some of the backlog normalizes, works itself out, but you are up against top comps. So should we just be thinking about that as really these initiatives around kind of the GP segment? And then kind of marketing and new direct-to-consumer and teen, that are really kind of what give you the confidence there? Or is there something else? Thanks.
了解。另外,你提到你們有信心達到長期區間 15% 到 25% 的上緣。那主要就是來自 GP 的各項計畫嗎?顯然部分積壓訂單會正常化、逐步消化,但你們也面臨很高的比較基期。所以我們是否應該把這份信心主要歸因於圍繞 GP 事業部的這些計畫?以及行銷、新的直面消費者(DTC)與青少年(teen)等,這些才是讓你們有信心的關鍵?還是有其他因素?謝謝。
Joe Hogan - President, CEO and Director
Joe Hogan - President, CEO and Director
Well, I mean, we didn't have easy comps this year when you look at -- we had easy comps on 2015 versus 2014. But this year we had, you know, Richard, pretty difficult comp, even what David just referenced in the fourth quarter last year, what a tough time we had.
嗯,我是說,從比較基期來看,今年其實也不算輕鬆——我們在 2015 對 2014 的確有比較容易的基期。但今年你知道的,Richard,我們的比較基期相當困難,甚至就像 David 剛提到的,去年第四季我們過得多辛苦。
So, look, I think when we talk about or when I talk about the GP focus that we are going to have, the international growth, the focus on teens next year, all those things are just to focus in areas where we develop products and systems over the course of the last 18 months that go after those areas that historically have been some soft areas for us, and maybe more predictable than they should have been. The rest of this business, you know the international parts, the Ortho utilization piece, those things are going really well.
所以你看,我認為當我們談到——或當我談到——我們將在 GP 上的聚焦、國際成長、明年對青少年的聚焦,這些都是把重心放在一些領域:在過去 18 個月裡我們開發了產品與系統,去切入那些歷來對我們而言相對疲弱、也許比應有程度更可預測(但偏軟)的領域。至於這個業務的其他部分,你知道的,國際的部分、Ortho 使用率那塊,這些進展都非常好。
David White - CFO
David White - CFO
Did we lose you -- hey, Richard, are you there?
我們是不是斷線了——嘿,Richard,你還在嗎?
Richard Newitter - Analyst
Richard Newitter - Analyst
Sorry, I was on mute. Yes. No. Thanks. That's very helpful. And just maybe one last one. The difference between -- what does GP Go do for you that kind of prior initiatives haven't in the past? And maybe just elaborate on that a little bit. Thank you.
抱歉,我剛剛開了靜音。在。沒有。謝謝。這很有幫助。再最後一個問題。GP Go 相較於過去的計畫,究竟能為你們帶來什麼不同?能否再多闡述一下?謝謝。
Joe Hogan - President, CEO and Director
Joe Hogan - President, CEO and Director
You know, Richard, basically GPs don't want to be Ortho's. They haven't been trained in tooth movements. And when you look at products like we have, like ClinCheck and our full case assessments and those things, they are -- as much as we want to make them simple, they are very sophisticated products. It's almost like using 90% of PowerPoint, which most people can't, right?
你知道的,Richard,基本上一般牙醫(GP)不想當矯正專科(Ortho)。他們沒有受過牙齒移動方面的訓練。而當你看像我們的產品,例如 ClinCheck、完整病例評估等,它們——即使我們希望把它們做得簡單——其實都是非常精密的產品。這有點像只用到 PowerPoint 的 90% 功能,而大多數人其實做不到,對吧?
And so with GPs, what we have to do is build their confidence in the sense that they can look at a case and quickly say, I can do this case and I can do it well for my patient or I can't. And just in a short kind of a statement, that's what Invisalign Go is. You can scan that patient or take a photo of that patient. We'll quickly assess that, and we'll tell that particular GP if they can actually handle that case. If they can, we can quickly work up a case assessment and give it to the customer while they're in the chair.
所以對 GP 而言,我們必須建立他們的信心:讓他們能看一個病例就快速判斷——我能做這個病例,而且能為我的病患做好;或者我不能。簡單一句話,這就是 Invisalign Go。你可以替那位病患掃描或拍照。我們會快速評估,並告訴該位 GP 他們是否真的能處理那個病例。如果可以,我們能迅速完成病例評估,並在病患還坐在診療椅上時就把結果提供給客戶。
It's a substantial difference than trying to, in two days, teach an Ortho -- I mean a GP how to do Ortho work, which is very difficult. We feel we can really integrate into a GP practice much more simply by making less complexity in a sense the way we do case assessments, and the burden it would place on a GP to take that kind of burden.
這與試圖在兩天內教一位矯正——我是說教一位 GP 做矯正工作——有很大的不同,那非常困難。我們認為,透過在病例評估的方式上降低複雜度,並減輕 GP 必須承擔的負擔,我們可以更簡單地真正融入 GP 的診所流程。
I hope that makes sense.
希望這樣說得通。
Richard Newitter - Analyst
Richard Newitter - Analyst
That does. Thank you.
說得通。謝謝。
Operator
Operator
Jeff Johnson, Robert W. Baird.
Jeff Johnson,Robert W. Baird。
Jeff Johnson - Analyst
Jeff Johnson - Analyst
Let me start just by saying, David, best of luck in retirement. It's been great working with you for the last three years or so. So, best of luck going forward.
我先說一句,David,祝你退休一切順利。過去三年左右能與你合作很愉快。所以,祝你未來一切順利。
David White - CFO
David White - CFO
Yes, thank you, Jeff. Appreciate that.
是的,謝謝你,Jeff。很感謝。
Jeff Johnson - Analyst
Jeff Johnson - Analyst
Yes. Yes, great. So, Joe, let me ask a couple of questions here. I mean, again, kind of like John, I hate to burn a question on the scanner business, but it's been so strong here. You know you mentioned kind of that being up next year.
是。很好。那 Joe,我這裡問幾個問題。我的意思是,跟 John 一樣,我也不太想把一個問題用在掃描器業務上,但它表現實在太強了。你提到明年那塊會成長。
If I look at your second-half numbers here, what's kind of implied in fourth-quarter guidance and the third-quarter's strong results, it looks like you are up 50-some-percent sequentially even first half to second half of this year. So, not to paint you in a corner, but kind of up year-over-year based off the 2016 base? Or do we keep seeing growth even off these low $30 million numbers, which are just well above what I think any of us were probably thinking they would be at this point?
如果我看你們今年下半年的數字,從第三季的強勁結果以及第四季指引所隱含的水準來看,似乎你們從上半年到下半年,序列成長大概有 50% 多。所以不是要把你逼到牆角,但以 2016 年的基期來看,明年會年增嗎?還是我們會繼續看到成長,即使是從這些 3,000 多萬美元的低基期往上長——這已經遠高於我想我們任何人在這個時間點原本預期的水準?
Joe Hogan - President, CEO and Director
Joe Hogan - President, CEO and Director
I mean growth over the 2016 base, Jeff.
我的意思是,相對於 2016 年基期的成長,Jeff。
Jeff Johnson - Analyst
Jeff Johnson - Analyst
2016 base. Yes. No, that's helpful. And then, David, maybe a clarifying question on the margin side. You made comments in your prepared remarks about margins. I think you said gross margins is down a little bit year-over-year next quarter, and you said that aligner ASP is down. You kind of made reference to some bigger promotions here in this quarter.
2016 年基期。是。不,這很有幫助。然後 David,我想在毛利率這邊問個釐清問題。你在準備好的講稿裡提到毛利率。我記得你說下季的毛利率會年減一點點,並且你說矯正器(aligner)的 ASP 下降。你也提到本季有一些較大的促銷活動。
I guess I'm trying to figure out why aligner ASP's would be down in the fourth quarter if you anniversary through the additional aligner thing, now you've got price increases? You also have the positive mix. If the backlog on North America is a little lower than the OUS backlog, I would think -- or the OUS growth -- I would think would be helping ASP's next quarter. So just trying to reconcile margins being down next quarter -- gross margins.
我想弄清楚的是:如果你們已經度過「額外矯正器」那件事的比較基期,現在又有漲價,為什麼第四季矯正器 ASP 會下降?你們也有正向的產品組合。如果北美的積壓訂單比 OUS 的積壓訂單少一些,我會以為——或以 OUS 的成長來看——我會以為這會在下季支撐 ASP。所以只是想把下季毛利率下滑——毛利率——這件事對起來。
David White - CFO
David White - CFO
So -- okay. So, for a couple things. One, as it relates to Clear Aligner, you know our -- well, more about ASP's, which will impact that. ASP's are affected by product mix. And our low stage products are very heavily concentrated, or more so concentrated, you might say, from a mix standpoint in our EMEA region than the rest of our business.
所以——好。所以,有幾件事。第一,關於透明矯正器(Clear Aligner),你知道我們——嗯,更主要是關於ASP(平均售價),這會影響到它。ASP 會受到產品組合的影響。而我們的低階產品非常高度集中,或者你可以說,從組合角度來看,在我們的 EMEA 地區比我們其他業務更為集中。
And so, since Q3 was a seasonally weaker quarter for EMEA and Q4 is a seasonally stronger, that mix of low stage product is going to enter into the equation and is going to influence the ASP's this next year. It will go up -- that mix is going to go up by one-plus points quarter-over-quarter. And that will have some bearing on it.
因此,由於第三季對 EMEA 來說是季節性較弱的一季,而第四季是季節性較強的一季,低階產品的組合就會納入考量,並且會影響明年的 ASP。它會上升——該組合將在季度對季度增加超過 1 個百分點。而這會對其產生一些影響。
And then secondly, you've got doctors -- this is the end of the advantage period for many of our doctors. And so as those doctors begin to get close to or approximate the next tier of their pricing, they will begin to see lower prices even this year early, as they are running towards that December 31 date. So those two things right there are bringing down the ASP and bringing down very, very modestly the gross margin at the same time.
第二,你會看到醫師——這是我們許多醫師優惠期的尾聲。因此,當這些醫師開始接近或達到下一個價格級距時,他們甚至在今年年初就會開始看到較低的價格,因為他們正朝著 12 月 31 日那個日期前進。所以,這兩件事會拉低 ASP,同時也會非常、非常小幅地拉低毛利率。
Jeff Johnson - Analyst
Jeff Johnson - Analyst
All right, that's helpful. And Joe, last question for me. I just want to make sure I understand clearly your comment on being in the upper half of that 15% to 25% range. I think you were talking Clear Aligners. And you were saying get back to that by first quarter of 2017? Or is that just kind of a general comment, getting back to that over the next few quarters?
好,這很有幫助。Joe,我最後一個問題。我只是想確認我清楚理解你關於處於 15% 到 25% 區間上半部的評論。我想你是在談透明矯正器(Clear Aligners)。你是說在 2017 年第一季前回到那個水準嗎?還是這只是比較概括的說法,表示在接下來幾季逐步回到那個水準?
Joe Hogan - President, CEO and Director
Joe Hogan - President, CEO and Director
Well, I, from an order rate standpoint, you know, Jeff, we feel we'll be in that range in the fourth quarter. So as we move into the first quarter of next year, we feel that way. And that is -- I'm quoting, as you mentioned, Clear Aligners. This is not mixing Clear Aligners with the scanner business.
嗯,我從訂單成長率的角度來看,Jeff,你知道,我們覺得第四季會落在那個區間。所以當我們進入明年第一季時,我們也有同樣的看法。而且——如你提到的,我說的是透明矯正器(Clear Aligners)。這不包含把透明矯正器與掃描器業務混在一起。
Jeff Johnson - Analyst
Jeff Johnson - Analyst
Yes. That's helpful. Thanks guys, appreciate it.
是的。這很有幫助。謝謝各位,感謝。
Joe Hogan - President, CEO and Director
Joe Hogan - President, CEO and Director
All right, Jeff. See you.
好,Jeff。回頭見。
Shirley Stacy - VP of Corporate Communications and IR
Shirley Stacy - VP of Corporate Communications and IR
Operator, we'll take one more question, please.
接線員,請再讓我們接一個問題。
Operator
Operator
Our final question comes from the line of Robert Jones of Goldman Sachs. Please proceed with your question, Mr. Jones.
我們最後一個問題來自高盛(Goldman Sachs)的 Robert Jones。Jones 先生,請提出您的問題。
Robert Jones - Analyst
Robert Jones - Analyst
Thanks for the questions. And, David, yes, congratulations on the retirement. John, look forward to working with you. I guess, Joe, just wanted to go back to something you had said about what you're seeing in case receipts quarter-to-date. Wanted to make sure I heard you correctly.
謝謝提問。David,是的,恭喜退休。John,期待與你合作。我想,Joe,我只是想回到你剛才提到的、你們在本季截至目前(quarter-to-date)看到的病例收件(case receipts)情況。我想確認我是否聽得正確。
It sounded like you are saying, based on what you are seeing to date, you do expect a return to the type of growth -- case growth that is that we saw in 2Q as we move into next year. Wanted to be clear that, A, I heard you correctly, and B, are you talking specifically about North American GPs? Or was that a reference to overall North American expectation for case growth?
聽起來你是在說,根據你們截至目前所看到的情況,你確實預期明年會回到我們在第二季看到的那種成長——也就是病例成長(case growth)。我想確認兩點:A,我是否聽得正確;B,你指的是北美的一般牙醫(GPs)嗎?還是你指的是北美整體對病例成長的預期?
Joe Hogan - President, CEO and Director
Joe Hogan - President, CEO and Director
The 20% that we're talking about is overall for the Clear Aligner business, is what we see right now in October for the entire business. We are seeing better North American performance than what we saw in the third quarter. I haven't specifically referenced if that was GP or Ortho.
我們所談的 20% 是透明矯正器(Clear Aligner)業務的整體數字,也就是我們目前在 10 月看到的全公司整體表現。我們看到北美的表現比第三季更好。我沒有特別說那是一般牙醫(GP)還是矯正專科(Ortho)。
David White - CFO
David White - CFO
And better than Q2 as well.
也比第二季更好。
Joe Hogan - President, CEO and Director
Joe Hogan - President, CEO and Director
Yes, better than Q2.
是的,比第二季更好。
Robert Jones - Analyst
Robert Jones - Analyst
Better than 2Q. Okay, got it. And then I guess just on the international side, it does look like the 4Q guidance for international cases seems to imply a bit of a slowdown there on a year-over-year basis. Just wanted to see if you could comment on some of the factors at play. Do you feel like you are reaching any kind of capacity constraints? Anything else as far as how quickly you can go after that big international opportunity?
比第二季更好。好,了解。接著我想問國際市場方面,看起來第四季對國際病例的指引似乎暗示年增率會有些放緩。想請你評論一下其中的一些因素。你們覺得是否碰到任何產能限制?或是就你們能多快去掌握那個龐大的國際機會而言,還有其他因素嗎?
Joe Hogan - President, CEO and Director
Joe Hogan - President, CEO and Director
So, Bob, our factory basically fabricates aligners on a first-in/first-out basis and without really much respect for where those aligners come from. And so, when we talk about our case receipts increasing this quarter, and our backlog and factory WHIP returning to a more normalized level, that cuts across both -- you know, all regions of our business.
所以,Bob,我們的工廠基本上是以先進先出(first-in/first-out)的方式製作矯正器,並不太在意這些矯正器來自哪個地區。因此,當我們談到本季病例收件增加、以及我們的積壓訂單(backlog)與工廠在製品(WHIP)回到較正常的水準時,這涵蓋了兩者——你知道,是涵蓋我們業務的所有地區。
And so, it has a -- whatever dampening effect it has, it is -- it's across all regions. And so, that's part of the reason.
因此,它所帶來的——不論有什麼抑制效果——都是跨所有地區的。所以,這是原因之一。
Robert Jones - Analyst
Robert Jones - Analyst
Okay.
好的。
Joe Hogan - President, CEO and Director
Joe Hogan - President, CEO and Director
The case -- on a case receipts side, though, international is very strong and it continues to be strong. Nothing's really changed there on the case receipts side.
不過就病例收件而言,國際市場非常強勁,而且持續強勁。在病例收件方面其實沒有什麼改變。
Robert Jones - Analyst
Robert Jones - Analyst
Okay, that's helpful. Thanks, guys.
好的,這很有幫助。謝謝各位。
Joe Hogan - President, CEO and Director
Joe Hogan - President, CEO and Director
Thank you, Bob.
謝謝你,Bob。
Shirley Stacy - VP of Corporate Communications and IR
Shirley Stacy - VP of Corporate Communications and IR
Thanks, Bob.
謝謝,Bob。
Operator
Operator
There are no further questions over the audio portion of the conference. I would now like to turn the conference back over to management for closing remarks.
音訊部分已沒有其他問題。現在我想把會議交回管理層作結語。
Shirley Stacy - VP of Corporate Communications and IR
Shirley Stacy - VP of Corporate Communications and IR
Thank you, operator. And thank you, everyone, for joining us today. We appreciate your time. If you have any follow-up questions, please contact Investor Relations.
謝謝你,接線員。也謝謝各位今天加入我們。我們感謝各位撥冗。如果你有任何後續問題,請聯絡投資人關係部門。
Operator
Operator
This concludes today's conference. Thank you for your participation. You may disconnect your lines at this time, and have a wonderful rest of your day.
今天的會議到此結束。感謝各位的參與。此時您可以掛斷電話線,祝您今天剩餘時間愉快。